Metformin and cancer. from diabetes to cancer: New therapeutic perspectives for metformin;Metformine et cancer. Du diabète au cancer : de nouvelles perspectives thérapeutiques pour la metformine

Medecine des Maladies Metaboliques

Volumn 5, Issue 1, 2011, Pages 29-37

  Viollet, Benoît ^a,b,c   Foretz, M ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

AMPK; cancer; diabetes; hyperinsulinemia; insulin resistance; metformin; mTOR

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIVER KINASE B1; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; TREATMENT INDICATION;

EID: 79953124747     PISSN: 19572557     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1957-2557(11)70183-3     Document Type: Article

References (58)

1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
2. Simon D. Diabète et cancer. Médecine des maladies Métaboliques 2009;3:320-7.
3. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-64.
4. Renehan AG. Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol 2009;10:640-1.
5. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
6. Beck E, Scheen AJ. Activité anticancéreuse de la metformine: nouvelles perspectives pour une vieille molécule. Rev Méd Suisse 2010;260:1601-7.
7. Foretz M, Viollet B. Mécanisme d'action hépatique de la metformine dans le diabète de type 2. Médecine des maladies Métaboliques 2009;3:48-54.
8. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-708.
9. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5. (Pubitemid 40813563)
10. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46:279-84.
11. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
12. Home PD, Kahn SE, Jones NP, et al.; ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucoselowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-45.
13. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20:1617-22.
14. Bodmer M, Meier C, Krähenbühl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8.
15. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
16. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938-46.
17. Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750-8.
18. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 2006;29:1990-1. (Pubitemid 44156679)
19. Monami M, Lamanna C, Pala L, et al. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients: a retrospective cohort study. Exp Clin Endocrinol Diabetes 2008;116:184-9. (Pubitemid 351518539)
20. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of timevarying exposure. Diabetologia 2010;53:1631-7.
21. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-6.
22. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.
23. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092-9.
24. Woodard J, Joshi S, Viollet B, et al. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010;10:1168-77.
25. Green AS, Chapuis N, Trovati Maciel T, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010;116:4262-73.
26. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005;40:685-93. (Pubitemid 41265819)
27. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21. (Pubitemid 351758227)
28. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008;99:2136-41.
29. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010;49:662-71.
30. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen - induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3:1066-76.
31. Bojkova B, Orendas P, Garajova M, et al. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009;56:269-74.
32. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-70. (Pubitemid 32246678)
33. Algire C, Amrein L, Zakikhani M, et al. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010;17:351-60.
34. Algire C, Zakikhani M, Blouin MJ, et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008;15:8339.
35. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11
36. [Erratum in: Cancer Res 2009;69:8832].
37. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465-75.
38. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74. (Pubitemid 32995375)
39. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69.
40. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6. (Pubitemid 41780780)
41. Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2010 [Epub ahead of print].
42. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008;8:501-5.
43. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69:6539-45.
44. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010;123:271-9.
45. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86. (Pubitemid 351793803)
46. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73. (Pubitemid 44799743)
47. Tremblay F, Brûlé S, Hee um S, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient-and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2007;104:14056-61. (Pubitemid 350003334)
48. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009;8:88-96.
49. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52. (Pubitemid 47105521)
50. Zhuang Y, Miskimins WK. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008;3:18.
51. Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009;27: e259; author reply e260.
52. Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103-7.
53. Phoenix KN, Vumbaca F, Claffey K P. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009;113:101-11.
54. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2369-80.
55. Janjetovic K, Vucicevic L, Misirkic M, et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 2011;651:41-50.
56. Gambineri A, Tomassoni F, Gasparini DI, et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2010;95: E204-8.
57. Goldenberg N, Glueck CJ. Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11 gene in polycystic ovary syndrome. Pharmacogenomics 2008;9:1163-5.
58. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009;8:2031-40.